Important Update for Myeloma Patients: Selinexor STORM Trials
Selinexor is an orally administered Selective Inhibitor of Nuclear Export, or SINE™, therapy for the treatment of multiple myeloma. Selinexor inhibits the transport of tumor suppressor proteins from the cell nucleus, where they detect cancerous DNA changes and induce cancer cell death. More than 900 patients have been treated with selinexor in phase I and phase II clinical trials and in an ongoing phase I clinical trial, Selinexor in combination with low-dose dexamethasone demonstrated favorable responses. To read more about the Selinexor STORM trials, please click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 20, 2015 Category: Hematology Source Type: news
Take IMF's Advocacy Survey on Myeloma and Medicare Coverage
The IMF Advocacy Team will meet with representatives from the Center for Medicare and Medicaid Services (CMS) next month to discuss current drug- and stem cell transplant-coverage policies. To prepare for the meeting, the IMF has created a short 14-question survey regarding your current Medicare coverage and any issues you may have had with it. Please take a few minutes to complete the survey so we can better understand the issues facing our myeloma community and take those to CMS in August. Please note the deadline to participate is Wednesday, August 19. To take the survey, please click HERE (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 17, 2015 Category: Hematology Source Type: news
Proposed "Value Framework" Could Limit Patient Access to Myeloma Drugs
The American Society of Clinical Oncology (ASCO) has created a "Value Framework" in an attempt to balance cancer drug costs with value to the patient. In his blog this week, IMF Chariman Dr. Brian Durie examines the framework's point system. "I believe the proposed system does not work well for myeloma," he writes, "and if implemented could limit needed drug access for myeloma patients." To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 14, 2015 Category: Hematology Source Type: news
Be a Part of the Los Angeles IMF Patient & Family Seminar
The IMF is hosting a two-day Patient & Family Seminar August 21-22 at the Sheraton Universal Hotel in Los Angeles, California. Attendees will receive the latest information on myeloma, access to many of the top myeloma experts, and a chance to share the company and support of other myeloma patients and family members. This event is not to be missed! For more information, or to register, please click HERE (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 13, 2015 Category: Hematology Source Type: news
Can a "Longevity Feast" Be the Key to Longer Life?
In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent New York Times interview with longevity expert Dan Buettner about putting on an Ikarian "Longevity Feast" inspired by his book, The Blue Zones Solution. The book takes a deep dive into five cultures around the world where people have the healthiest and longest lives. While a healthy diet is certainly a cornerstone to vibrant life, Dr. Durie writes that, "spending time with the right mix of friends and family is very important. This natural or organic stress reduction has almost a magical effect." To read the full post, click HERE (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 7, 2015 Category: Hematology Source Type: news
The International Myeloma Foundation (IMF) Announces Publication of
New Diagnostic Guidelines to Better Assess Patients and Guide Treatment
< p > Revisions to the International Staging System by the IMF & rsquo;s International Myeloma Working Group Reported in the Journal of Clinical Oncology < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 5, 2015 Category: Hematology Source Type: news
The International Myeloma Foundation (IMF) Announces Publication of
New Diagnostic Guidelines to Better Assess Patients and Guide Treatment
Revisions to the International Staging System by the IMF’s International Myeloma Working Group Reported in the Journal of Clinical Oncology (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 5, 2015 Category: Hematology Source Type: news
Click here to watch the "Advocacy in August: How to Connect with your Representative at Home" replay
With the Congressional August recess in full swing, this webinar will give you the tools to educate your members of Congress on the issues that matter most to you and the multiple myeloma community. Whether you're new to advocacy or a veteran, this webinar is not to be missed! The presentation will focus on breaking down the advocacy process, helping you understand the issues, and teaching you how to get the most out of the resources available to you. To watch the replay, please click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 31, 2015 Category: Hematology Source Type: news
Register for Webinar "Advocacy in August: How to Connect with your Representative at Home"
Please join the IMF Advocacy Team on Wednesday, August 5th at 7:00 PM ET, 4:00 PM PT for their webinar, “Advocacy in August: How to Connect with your Representative at Home.” With the Congressional August recess in full swing, this webinar will give you the tools to educate your members of Congress on the issues that matter most to you and the multiple myeloma community. Whether you're new to advocacy or a veteran, this webinar is not to be missed! The presentation will focus on breaking down the advocacy process, helping you understand the issues, and teaching you how to get the most out of the resources available to ...
Source: International Myeloma Foundation - July 31, 2015 Category: Hematology Source Type: news
Is There a Link Between a Genetic Variation and Poor Myeloma Survival Rate?
In his blog this week, IMF Chairman Dr. Brian Durie comments on news about a multi-institutional study that found patients with multiple myeloma with a genetic variation in the gene FOPNL have poorer outcomes than patients without it. “As one might suspect, much further work is needed to substantiate and understand this finding,” he notes, “but this initial report is quite tantalizing.” To read Dr. Durie's blog, click HERE (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 30, 2015 Category: Hematology Source Type: news
European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 27, 2015 Category: Hematology Source Type: news
FDA Approves Kyprolis & #174; (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma
< p > Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 24, 2015 Category: Hematology Source Type: news
FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma
Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 24, 2015 Category: Hematology Source Type: news
IMF's Black Swan Research Initiative Makes Inroads on Pathway to a Cure
The Black Swan Research Initiative® is moving ahead on all fronts, reports IMF Chairman Dr. Brian Durie in his blog this week. “The stage is set to include standardized MRD testing into clinical trials. And we continue to work on additional and simpler testing, such as a new blood test for early diagnosis and monitoring.” Also this week, a follow-up on possible connections between sitting too much and myeloma—but not what you'd expect! To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 23, 2015 Category: Hematology Source Type: news
Members of International Myeloma Foundation's Nurse Leadership Board
Author Key Textbook for Nurses
< p > Book Updates the First Comprehensive Review by and For Nurses & nbsp; < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 22, 2015 Category: Hematology Source Type: news
